Protected: Case Study: How MadeAi Accelerates Evidence Synthesis for Life Sciences Teams
There is no excerpt because this is a protected post.
June 3, 2026
There is no excerpt because this is a protected post.
In 5 years, the most valuable people in Life Sciences won’t just understand validation.
They’ll understand how to govern intelligence that evolves.
That distinction sounds subtle.
It isn’t.
It changes everything about risk, compliance, monitoring, and quality oversight.
27 months. That’s how quickly a European AI roadmap can slip if you misread the EU AI Act—and the coming delay could cost you even more
Recently, one of our readers reached out with a very practical question about digitalising QA: they were choosing between Kneat and ValGenesis as validated software
Four out of five MedTech teams we speak to act as if their eQMS makes them audit‑ready. Then the first FDA inspection hits, and that assumption doesn’t hold up
Two systems. One critical mistake. And the question most GxP leaders get wrong: where does your eQMS stop—and your data integrity risk begin?